Send to

Choose Destination
Curr Med Chem. 2018 May 31. doi: 10.2174/0929867325666180601100235. [Epub ahead of print]

Pharmacological Management of Chronic Obstructive Lung Disease (COPD). Focus on Mutations.

Author information

Unit of Clinical and Molecular Epidemiology, IRCCS San Raffaele Pisana Via di Valcannuta, 247, I-00166 Rome, Italy
Unit of Thoracic Surgery, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy
Unit of Pulmonary Rehabilitation, IRCCS San Raffaele Pisana Via di Valcannuta, 247, I-00166 Rome,Italy
Scientific Direction, IRCCS San Raffaele Pisana Via di Valcannuta, 247, I-00166 Rome, Italy



We report a comprehensive overview of current Chronic Obstructive Lung Disease (COPD) therapies and discuss the development of possible new pharmacological approaches based on "new" knowledge. Specifically sensitivity/resistance to corticosteroids is evaluated with a special focus on the role of gene mutations in drug response.


Critically review the opportunities and the challenges occurring into the treatment of COPD.


Findings from "omics" trials should be used to learn more about biologic targeted drugs, and to select more specific drugs matching patient's distinctive molecular profile. Specific markers of inflammation such as percentage of eosinophils are important in determining sensitivity/resistance to corticosteroids. Specific gene variations (Single nucleotide polymorphisms: SNPs) may influence drug sensitivity or resistance. Clinicians working in a real-world need to have a suitable interpretation of molecular results together with a treatment guidance and recommendations. Far more translational research is required before new results from omics techniques can be applied in personalized medicine in real-world settings.


COPD; SNPs; classical-therapy; complexity; eosinophils ; personalized-medicine; real-life analysis; systems approaches.

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center